Close Menu

People in the News

Aug 26, 2020

Synthego: Robert Deans and John Tan

Synthego has appointed Robert Deans as CSO and John Tan as chief operating officer.

Deans has more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise. He previously served in executive roles at BlueRock Therapeutics and Rubius Therapeutics, where he participated in the creation of next-generation therapies through the use of pluripotent stem cell biology and gene editing tools, Synthego said.

Tan has decades of global operations and automation expertise in various technology and life sciences companies, including Amazon and Thermo Fisher Scientific. At Thermo Fisher, he managed global planning, quality, regulatory, procurement, supply chain, and continuous improvement functions across more than 20 sites in the US, Europe, and Asia.

Aug 26, 2020

Bionano Genomics: Christopher Stewart

Bionano Genomics announced that Christopher Stewart will join as CFO, effective Sept. 1, 2020.

Stewart joins Bionano from Tesla, where he headed the ultracapacitor business unit. Prior to that, he was VP of finance and information technology at Maxwell Technologies, which was acquired by Tesla. Stewart was also CFO of V-Enable, now xAD, a mobile advertising firm, and was VP of finance at Entropic Communications.

Aug 25, 2020

Illumina: Kathryne Reeves

Illumina has announced that Kathryne Reeves will join the firm as chief marketing officer on Sept. 28, 2020, reporting to CEO Francis deSouza.

Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical services global business unit. Prior to that, she held positions at Booz Allen Hamilton, AOL/TimeWarner, Nationwide Insurance, and Scotts Miracle-Gro.

Reeves holds an MBA from Harvard Business School.

Aug 24, 2020

AusDiagnostics: Scott Gilroy

AusDiagnostics appointed Scott Gilroy as its new CEO, effective Aug. 24. Gilroy was previously chief operations officer at the company and will take over from Keith Stanley, who will serve as managing director. Gilroy has served in many positions at Malvern Panalytical, including as the general manager for the Australia/New Zealand and Oceania division, regional head of sales and marketing for Asia Pacific, and national sales and marketing manager. 

Aug 21, 2020

Qiagen: Lawrence Rosen

Qiagen has appointed Lawrence Rosen as the chairman of the firm's supervisory board. He will replace Håkan Björklund, who will step down as chairman and as a member of Qiagen's supervisory board. 

Rosen currently has served as a member of Qiagen's supervisory board since 2013. He also serves on the supervisory board of German firm Lanxess. Rosen previously served as a member of the board of management and CFO at Deutsche Post DHL Group until 2016. Prior to that, he held the role of CFO of Fresenius Medical Care from 2003 to 2009. Prior to Fresenius Medical Care, Rosen was senior VP and treasurer for Aventis. Between 1984 and 2000, he held various positions at Avenis predecessor companies Hoechst and American Hoechst/Hoechst Celanese. 

Aug 21, 2020

Illumina: Karen McGinnis

Illumina VP and Chief Accounting Officer Karen McGinnis has notified the firm that she will retire April 2, 2021.

Aug 20, 2020

IonPath: Sander Gubbens

IonPath has appointed Sander Gubbens as CEO. He replaces company cofounder Harris Fienberg.

Gubbens was most recently president of Gatan, a cryo-electron microscopy firm, which was acquired by Amtek in 2019 for $925 million. He has over 30 years of experience in developing and commercializing technology in the life science, materials science, and semiconductor industries. Prior to Gatan, he held senior R&D roles at KLA-Tencor.

An inventor on 17 patents and a member of the board of PCR instrument maker Combinati, Gubbens holds a doctorate in applied physics from The Netherlands' Delft University of Technology and an MBA from the University of California, Berkeley Hass School of Business.

Aug 18, 2020

Becton Dickinson: Kristen Stewart

Becton Dickinson has appointed Kristen Stewart to the newly created position of Senior Vice President of Strategy and Investor Relations, reporting to BD's CFO Chris Reidy. Stewart will work with the BD executive team beginning Aug. 31 to drive shareholder value and to deliver and communicate the company's long-term growth strategy, BD said in a statement. Stewart has worked with investment banks for nearly two decades as a healthcare analyst specializing in medical technology, most recently leading the medical technology research division at Barclays Capital.

Aug 18, 2020

Alveo Technologies: Julianne Averill

Infectious disease diagnostic firm Alveo Technologies recently announced the appointment of Julianne Averill as CFO. She will be responsible for leading all financial operations and implementing strategies to accelerate Alveo's growth, the company said in a statement. Averill has 18 years of leadership experience and most recently served as VP of Finance for BlackThorn Therapeutics. Before that, she held leadership positions at Manifest MedEx and Starwood Waypoint Residential Trust and served as an audit manager at Deloitte. Averill has also participated in or led strategic financing and M&A initiatives totaling more than $2 billion. 

Aug 18, 2020

Bionano Genomics: Alka Chaubey

Bionano Genomics has appointed Alka Chaubey as its first chief medical officer, effective Aug. 31, 2020.

Chaubey, a cytogeneticist, will be responsible for driving adoption of the firm's Saphyr optical genome mapping platform for use in clinical applications.

She brings nearly 20 years of scientific and clinical experience and has developed and validated clinical tests, including US Food and Drug Administration-cleared whole-genome cyotgenetic tests. She comes to Bionano from PerkinElmer, where she is head of the cytogenomics. She is also an adjunct assistant professor of pathology at the Medical College of Georgia at Augusta University and is scientific director of the Georgia Esoteric and Molecular Laboratory and the Augusta University Medical Center cytogenetics laboratory. Before coming to PerkinElmer, she directed the Greenwood Genetic Center's cytogenomics laboratory.

Chaubey holds a doctorate in biochemistry and molecular biology from India's Guru Nanak Dev University.

Aug 17, 2020

ACMG Foundation for Genetic and Genomic Medicine: Robert Best

The ACMG Foundation for Genetic and Genomic Medicine has appointed Robert Best to its board of directors. Best currently serves as professor of biomedical sciences at the University of South Carolina School of Medicine Greenville. In addition, Best serves as director of the clinical laboratories and prenatal screening and the division of genetics and molecular medicine in the obstetrics and gynecology department at USC's School of Medicine. 

Aug 13, 2020

Myriad Genetics: Paul Diaz

Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine. 

Aug 07, 2020

Pacific Biosciences: Christian Henry, Michael Hunkapiller, John Milligan, Ben Gong

Pacific Biosciences has appointed Christian Henry as president and CEO effective Sept. 14, 2020. Henry has served on the board of directors since 2018, including as chairman since March 2020.

John Milligan, a board member since 2013, has been appointed to succeed Henry as chairman, also effective Sept. 14.

As previously announced, Michael Hunkapiller will retire from an active operating role at the end of the year. Effective Sept. 14, Hunkapiller will assume the position of senior fellow focused on technology development until his retirement. Hunkapiller will also continue to serve on the company's board.

In addition, Pacific Biosciences has named Ben Gong as interim CFO to succeed Susan Barnes, who's retirement from the position was previously announced.

Aug 07, 2020

Tangen Biosciences: Vance Kershner, Alan Levin

Tangen Biosciences has appointed Vance Kershner and Alan Levin to its board of directors in conjunction with a $12.2 million Series B preferred stock financing. Kershner is founder, president, and CEO of LabWare, which develops and implements software for automating laboratory operations. Levin previously served as president and CEO of drugstore chain Happy Harry's, which merged with the Walgreen Company in 2006. Levin also previously served as the Director of the Delaware Economic Development Office.

Aug 06, 2020

Crown Bioscience: John Gu

Crown Bioscience has been appointed John Gu as chief operations officer. Gu joins Crown Bio from WuXi Nextcode, where he was general manager for the China business and chief digital officer. Prior to WuXi, Gu was held successive senior technology and operations roles across digital and technology companies, including Alcatel-Lucent. 

Aug 05, 2020

Integrity Laboratories: Maria Cekanova

Integrity Laboratories has appointed Maria Cekanova CSO. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity recently received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.

Aug 04, 2020

Lexogen: Stéphane Barges, Alexander Seitz

Sequencing firm Lexogen has appointed Stéphane Barges as CEO, effective Sept. 1. 

Barges comes to Lexogen from Qiagen, where he was VP of molecular diagnostics. He has 20 years of experience in the life science and clinical diagnostics industry, including management positions at Life Technologies, Bio-Rad Laboratories, and Tecan. He holds a doctorate in genetics and molecular biology from the University of Geneva and an MBA from HEC Geneva.

Barges will succeed Lexogen founder Alexander Seitz, who will take on the role of chief innnovation officer.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 30, 2020

ACMG Foundation for Genetic and Genomic Medicine: Nasha Fitter

The ACMG Foundation for Genetic and Genomic Medicine, a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice, has elected Nasha Fitter to its board of directors. Fitter currently serves as director of Rare and Neurological Diseases at Ciitizen. She is also cofounder, CEO, and head of research at FOXG1 Research Foundation, an organization focused on finding a cure for FOXG1 syndrome. Previously, Fitter founded and served as CEO of Schoolie, and prior to that worked as director of the Global Schools Program at Microsoft Education.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Pages

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.